• Finance Tax Investment

£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park

Science Park helping to drive local economic growth with SELEP support

Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine

- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment - Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills - New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics

Locate Bio raises £2.25m for new spinal treatments

Locate Bio, who are developing new treatments for patients with serious spinal conditions, has completed a £2.25m funding round led by Mercia Asset Management to help to continue its ground-breaking research and bring its first products to market

CGT Catapult Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry

The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.

Fieldfisher Life Sciences sector group advise on £48 million fundraise by AIM listed Avacta Group plc to fund COVID-19 test

European law firm Fieldfisher has advised finnCap and Zeus Capital, in their capacities as joint brokers to AIM-listed Avacta Group plc, a leading life sciences company, on its heavily oversubscribed £48 million fundraising to develop a saliva-based rapid antigen COVID-19 test.

Fieldfisher Life Sciences sector group mobilises to offer pro bono legal advice for COVID-19

Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.

Gene therapy: the challenge and the opportunity

By Annie Zeng Gene therapy is an experimental and therapeutic technique involving the engineering of genes with the hope to cure disease at its root cause. This has become an increasingly buoyant area for investment and although still at an early phase of development, there have been recent approvals of clinical and commercial gene therapies for use in humans.

£1.2m investment to reinforce Stevenage Campus as world class cell and gene therapy hub

Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster. The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing cell and gene therapy companies, strengthening the UK’s sectorial advantage and Hertfordshire’s position within the Oxford-London-Cambridge golden research triangle.

UKI2S Innovate Accelerator reaches entrepreneurial start-ups in all parts of the UK

UK Innovation & Science Seed Fund (UKI2S) has celebrated the first anniversary of its UKI2S Innovate Accelerator, a joint funding initiative with Innovate UK (IUK) directed at early stage science and engineering companies.

£11 million boost for leading antibody development company MedAnnex Ltd

Edinburgh-based biotechnology company MedAnnex Ltd has received a further £1 million investment from The Scottish Investment Bank (SIB), the investment arm of Scotland’s national economic development agency, Scottish Enterprise. This adds to a recent £10 million Series B investment, by Boston-based global Life Sciences investor Morningside Ventures, to close an £11 million funding round for MedAnnex.